Detalhe da pesquisa
1.
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve (AMBER) and virologically suppressed (EMERALD) participants with neurological and/or psychiatric comorbidities: Week 96 subgroup analysis.
HIV Med
; 24(3): 279-289, 2023 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36912173
2.
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study.
Clin Infect Dis
; 71(12): 3110-3117, 2020 12 15.
Artigo
Inglês
| MEDLINE | ID: mdl-31879782
3.
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.
AIDS Res Ther
; 16(1): 23, 2019 08 29.
Artigo
Inglês
| MEDLINE | ID: mdl-31464642
4.
Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen.
Antimicrob Agents Chemother
; 61(12)2017 12.
Artigo
Inglês
| MEDLINE | ID: mdl-28971875
5.
Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection.
BMC Gastroenterol
; 17(1): 26, 2017 Feb 10.
Artigo
Inglês
| MEDLINE | ID: mdl-28187751
6.
Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.
Gastroenterology
; 146(3): 744-753.e3, 2014 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-24316262
7.
An OPTIMIZE study retrospective analysis for management of telaprevir-treated hepatitis C virus (HCV)-infected patients by use of the Abbott RealTime HCV RNA assay.
J Clin Microbiol
; 53(4): 1264-9, 2015 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-25653396
8.
Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study.
Liver Int
; 35(2): 448-54, 2015 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-25319731
9.
Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment-experienced patients.
J Hepatol
; 60(6): 1112-7, 2014 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-24486089
10.
Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir.
Virol J
; 11: 93, 2014 May 16.
Artigo
Inglês
| MEDLINE | ID: mdl-24886541
11.
Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial.
J Infect Dis
; 208(6): 1000-7, 2013 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-23801602
12.
Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.
Gastroenterology
; 140(2): 459-468.e1; quiz e14, 2011 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-21034744
13.
Low Incidence and Brief Duration of Gastrointestinal Adverse Events with Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Over 96 Weeks: Post hoc Analyses of AMBER and EMERALD.
J Int Assoc Provid AIDS Care
; 21: 23259582221088202, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-35466761
14.
Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in acute and early HIV-1 infection: a DIAMOND subgroup analysis.
HIV Res Clin Pract
; 22(2): 55-61, 2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-33999786
15.
Pooled resistance analyses of darunavir once-daily regimens and formulations across 10 clinical studies of treatment-naïve and treatment-experienced patients with human immunodeficiency virus-1 infection.
HIV Res Clin Pract
; 21(2-3): 83-89, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-32715952
16.
Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT study.
Health Sci Rep
; 3(2): e145, 2020 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-32270053
17.
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study.
HIV Res Clin Pract
; 20(1): 24-33, 2019 02.
Artigo
Inglês
| MEDLINE | ID: mdl-31303147
18.
Correction to: Evaluation of Cardiovascular Disease Risk in HIV1-Infected Patients Treated with Darunavir.
Drugs R D
; 18(3): 249-250, 2018 09.
Artigo
Inglês
| MEDLINE | ID: mdl-30079430
19.
Evaluation of Cardiovascular Disease Risk in HIV-1-Infected Patients Treated with Darunavir.
Drugs R D
; 18(3): 199-210, 2018 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-29992490
20.
HIV-1 resistance rarely observed in patients using darunavir once-daily regimens across clinical studies.
HIV Clin Trials
; 18(5-6): 196-204, 2017.
Artigo
Inglês
| MEDLINE | ID: mdl-29143565